Cargando…

Ponatinib both as an effective bridge to allogeneic hematopoietic stem cell transplantation and as posttransplant maintenance therapy in a chronic myeloid leukemia patient with myeloid blast crisis

Detalles Bibliográficos
Autores principales:	Küçükyurt, Selin, Kelezoğlu, Alihan, Elverdi, Tuğrul, Özmen, Deniz, Ar, Muhlis Cem, Eşkazan, Ahmet Emre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Hematologia e Hemoterapia 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244240/ https://www.ncbi.nlm.nih.gov/pubmed/34210618 http://dx.doi.org/10.1016/j.htct.2021.04.007

Ejemplares similares

The Impact of the COVID-19 Pandemic on the Diagnosis and Management of Patients with Classical Hodgkin Lymphoma: A Single-Center Experience
por: Kucukyurt, Selin, et al.
Publicado: (2021)

Diagnosis and Management of Classical Hodgkin Lymphoma During the COVID-19 Pandemic()
por: Küçükyurt, Selin, et al.
Publicado: (2022)

Upregulation of SPINK2 in acute myeloid leukemia
por: Gezer, Sümbül, et al.
Publicado: (2023)

Treatment Responses, Toxicity, and Survival in Patients with Classical Hodgkin Lymphoma Aged ≥50 Years: A Single-Center Experience Over Two Decades
por: Çokgezer, Simay, et al.
Publicado: (2022)

Impact of the COVID-19 pandemic on the regular follow-up and outcomes of patients with chronic myeloid leukemia in chronic-phase
por: Yılmaz, Umut, et al.
Publicado: (2022)

Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience
por: Öngören, Şeniz, et al.
Publicado: (2017)

Therapy‐related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor
por: Kucukyurt, Selin, et al.
Publicado: (2020)

Efficacy of ponatinib prior to and after allogeneic hematopoietic stem cell transplantation in an adolescent with chronic myeloid leukemia in blast phase
por: Lee, Jae Wook, et al.
Publicado: (2021)

Vincristine as an Adjunct to Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura: A Single-Institution Experience
por: Öngören, Seniz, et al.
Publicado: (2018)

Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve Outcomes
por: Kucukyurt, Selin, et al.
Publicado: (2020)

Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura
por: Elverdi, Tugrul, et al.
Publicado: (2019)

The prognostic value of serum levels of a proliferation-inducing ligand (APRIL) in treatment-naïve patients with chronic lymphocytic leukemia
por: ESATOĞLU, Sinem Nihal, et al.
Publicado: (2021)

New kid on the block: C-reactive protein-to-albumin ratio as a new prognostic marker for chronic lymphocytic leukemia: Comment on “C-reactive protein-to-albumin ratio is an independent poor prognostic factor in newly diagnosed chronic lymphocytic leukaemia: A clinical analysis of 322 cases”
por: Küçükyurt, Selin, et al.
Publicado: (2021)

Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case
por: Bucelli, Cristina, et al.
Publicado: (2017)

Elevación de SPINK2 en leucemia mieloide aguda
por: Gezer, Sümbül, et al.
Publicado: (2023)

BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia
por: Parry, Narissa, et al.
Publicado: (2022)

Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia
por: Price, Kimberly E, et al.
Publicado: (2013)

A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia
por: Korfi, K., et al.
Publicado: (2015)

Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia
por: Musumeci, Francesca, et al.
Publicado: (2018)

Asciminib in chronic myeloid leukemia: many questions still remain to be answered
por: Eşkazan, Ahmet Emre
Publicado: (2021)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
por: Tiribelli, Mario, et al.
Publicado: (2019)

Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities
por: Ren, Mingqiang, et al.
Publicado: (2012)

Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia
por: Molica, Matteo, et al.
Publicado: (2019)

Pediatric chronic myeloid leukemia in myeloid blast crisis
por: Dey, Biswajit, et al.
Publicado: (2023)

Current Management of Chronic Myeloid Leukemia Myeloid Blast Phase
por: Yohanan, Binoy, et al.
Publicado: (2022)

Gilteritinib as Bridging and Posttransplant Maintenance for Relapsed Acute Myeloid Leukemia with FLT3-ITD Mutation Accompanied by Extramedullary Disease in Elderly
por: Saburi, Masuho, et al.
Publicado: (2023)

Interstitial Pneumonitis in a Patient with Chronic Myeloid Leukemia
por: Eşkazan, Ahmet Emre, et al.
Publicado: (2013)

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations
por: Keskin, Dilek, et al.
Publicado: (2016)

PB1899: DEVELOPMENT AND VALIDATION OF A PREDICTIVE SCORING SYSTEM FOR THE PROGNOSIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE RECEIVING FIRST-LINE IMATINIB
por: Bektaş, M., et al.
Publicado: (2022)

Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience
por: Özbalak, Murat, et al.
Publicado: (2022)

Editorial: Advances in the treatment of chronic myeloid leukemia
por: Eşkazan, Ahmet Emre, et al.
Publicado: (2023)

Recurrent Monosomies Confirmed by Interphase FISH in Three Chronic Myeloid Leukemia Cases
por: Tarkan Argüden, Yelda, et al.
Publicado: (2015)

Cutaneous Lesions Anticipating Accelerated Phase of Multidrug Resistant Chronic Myeloid Leukemia Responsive to Ponatinib
por: Breccia, Massimo, et al.
Publicado: (2016)

In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features
por: Tusa, Ignazia, et al.
Publicado: (2020)

Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
por: Luna, A., et al.
Publicado: (2022)

466 Skin lesions in febrile neutropenic patients
por: Yemisen, Mucahit, et al.
Publicado: (2014)

Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia
por: Eşkazan, Ahmet Emre, et al.
Publicado: (2013)

Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
por: Castagnetti, Fausto, et al.
Publicado: (2021)

P680: PONATINIB 15 MG AS CONSOLIDATION PRIOR TO TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA
por: Garcia Gutierrez, Valentin, et al.
Publicado: (2023)

Diagnostic and Treatment Obstacles in Acute Myeloid Leukemia: Social, Operational, and Financial
por: Genç, Emine Eylem, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_oes3f1b6k6evrnkvd3r4iolto8